Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study

Jason C Gallagher, Michael J Satlin, Abdulrahman Elabor, Nidhi Saraiya, Erin K McCreary, Esther Molnar, Claudine El-Beyrouty, Bruce M Jones, Deepali Dixit, Emily L Heil, Kimberly C Claeys, Jon Hiles, Nikunj M Vyas, Christopher M Bland, Jin Suh, Kenneth Biason, Dorothy McCoy, Madeline A King, Lynette Richards, Nicole Harrington, Yi Guo, Saira Chaudhry, Xiaoning Lu, Daohai Yu, Jason C Gallagher, Michael J Satlin, Abdulrahman Elabor, Nidhi Saraiya, Erin K McCreary, Esther Molnar, Claudine El-Beyrouty, Bruce M Jones, Deepali Dixit, Emily L Heil, Kimberly C Claeys, Jon Hiles, Nikunj M Vyas, Christopher M Bland, Jin Suh, Kenneth Biason, Dorothy McCoy, Madeline A King, Lynette Richards, Nicole Harrington, Yi Guo, Saira Chaudhry, Xiaoning Lu, Daohai Yu

Abstract

Background: Multidrug-resistant Pseudomonas aeruginosa infections remain common in hospitals worldwide. We investigated the outcomes associated with the use of ceftolozane-tazobactam for the treatment of these infections.

Methods: Data were collected retrospectively from 20 hospitals across the United States about adults who received ceftolozane-tazobactam for the treatment of multidrug-resistant P aeruginosa infections of any source for at least 24 hours. The primary outcome was a composite of 30-day and inpatient mortality, and secondary outcomes were clinical success and microbiological cure. Multivariable regression analysis was conducted to determine factors associated with outcomes.

Results: Two-hundred five patients were included in the study. Severe illness and high degrees of comorbidity were common, with median Acute Physiology and Chronic Health Evaluation (APACHE) II scores of 19 (interquartile range [IQR], 11-24) and median Charlson Comorbidity Indexes of 4 (IQR, 3-6). Delayed initiation of ceftolozane-tazobactam was common with therapy started a median of 9 days after culture collection. Fifty-nine percent of patients had pneumonia. On susceptibility testing, 125 of 139 (89.9%) isolates were susceptible to ceftolozane-tazobactam. Mortality occurred in 39 patients (19%); clinical success and microbiological cure were 151 (73.7%) and 145 (70.7%), respectively. On multivariable regression analysis, starting ceftolozane-tazobactam within 4 days of culture collection was associated with survival (adjusted odds ratio [OR], 5.55; 95% confidence interval [CI], 2.14-14.40), clinical success (adjusted OR, 2.93; 95% CI, 1.40-6.10), and microbiological cure (adjusted OR, 2.59; 95% CI, 1.24-5.38).

Conclusions: Ceftolozane-tazobactam appeared to be effective in the treatment of multidrug-resistant P aeruginosa infections, particularly when initiated early after the onset of infection.

Keywords: Gram-negative; Pseudomonas; ceftolozane-tazobactam; multidrug-resistant infections; resistance.

References

    1. Karlowsky JA, Lob SH, Young K, et al. . Activity of imipenem-relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions—SMART 2015–2016. J Glob Antimicrob Resist 2018; 15:140–7.
    1. Furtado GH, d’Azevedo PA, Santos AF, et al. . Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30:315–9.
    1. Vidal L, Gafter-Gvili A, Borok S, et al. . Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2007; 60:247–57.
    1. Zhanel GG, Chung P, Adam H, et al. . Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014; 74:31–51.
    1. Toussaint KA, Gallagher JC. β-lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother 2015; 49:86–98.
    1. Magiorakos AP, Srinivasan A, Carey RB, et al. . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–81.
    1. Harris PA, Taylor R, Thielke R, et al. . Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–81.
    1. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309–32.
    1. Hall WH, Ramachandran R, Narayan S, et al. . An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4:94.
    1. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818–29.
    1. Zerbaxa(R) (Ceftolozane and Tazobactam) for Injection, for Intravenous Use [package insert]. Whitehouse Station, NJ: Merck and Co, Inc; 2016.
    1. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; 28th Informational Supplement. CLSI document M100-S28. Wayne, PA: Clinical Laboratory Standards Institute; 2018.
    1. Tumbarello M, Repetto E, Trecarichi EM, et al. . Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect 2011; 139:1740–9.
    1. Micek ST, Lloyd AE, Ritchie DJ, et al. . Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306–11.
    1. Lodise TP Jr, Patel N, Kwa A, et al. . Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 2007; 51:3510–5.
    1. Kang CI, Kim SH, Kim HB, et al. . Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745–51.
    1. Tam VH, Rogers CA, Chang KT, et al. . Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 2010; 54:3717–22.
    1. Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. . Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43–8.
    1. Peña C, Suarez C, Gozalo M, et al. . Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56:1265–72.
    1. Sacha GL, Neuner EA, Athans V, et al. . Retrospective evaluation of the use of ceftolozane/tazobactam at a large academic medical center. Infect Dis Clin Pract 2017; 25:5.
    1. Haidar G, Philips NJ, Shields RK, et al. . Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 2017; 65:110–20.
    1. Munita JM, Aitken SL, Miller WR, et al. . Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis 2017; 65:158–61.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi